BM
BMRN.US Biomarin Pharmaceutical Inc
- Market cap
- USD 11.1B
- P/E
- -
- P/B
- 1.76x
- ROE
- 0.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BMRN.US undervalued?
Graham numberThe Graham number of Biomarin Pharmaceutical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biomarin Pharmaceutical Inc fundamental analysis
No fundamental analysis for Biomarin Pharmaceutical Inc yet.
Biomarin Pharmaceutical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c…
Full company profileBiomarin Pharmaceutical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biomarin Pharmaceutical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.12B | 1.31B | 1.49B | 1.70B | 1.86B | 1.85B | 2.10B | 2.42B | 2.85B | 3.22B | 3.71B |
| Gross Profit | 907M | 1.07B | 1.18B | 1.34B | 1.34B | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B | 2.90B |
| Operating Income | -803M | -14.7M | -124M | -100M | -43.4M | -82.3M | 161M | 186M | 484M | 533M | 211M |
| EBITDA | -698M | 91.0M | -3.37M | 31.9M | 83.7M | 47.4M | 265M | 307M | 651M | 573M | 599M |
| Net Income | -630M | -117M | -77.2M | -23.8M | 854M | -64.1M | 142M | 168M | 427M | 349M | 36.6M |
| EPS | -3.79 | -0.67 | -0.44 | -0.13 | 4.46 | -0.35 | 0.75 | 0.87 | 2.17 | 1.77 | 0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 4.02B | 4.63B | 4.43B | 4.69B | 5.85B | 6.00B | 6.38B | 6.84B | 6.99B | 7.59B | 11.6B |
| Total Liabilities | 1.26B | 1.82B | 1.46B | 1.57B | 1.74B | 1.73B | 1.77B | 1.89B | 1.33B | 1.51B | 5.31B |
| Shareholders' Equity | 2.77B | 2.81B | 2.97B | 3.12B | 4.11B | 4.27B | 4.60B | 4.95B | 5.66B | 6.09B | 6.26B |
| Cash & Short-term Investments | 790M | 1.40B | 1.08B | 754M | 1.07B | 1.01B | 1.29B | 1.07B | 1.14B | 1.56B | 736M |
| Total Debt | 683M | 1.17B | 830M | 859M | 1.09B | 1.09B | 1.09B | 1.10B | 649M | 643M | 4.19B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -228M | -8.76M | 20.2M | 48.3M | 85.4M | 305M | 176M | 159M | 573M | 828M | 769M |
| Capital Expenditure | 148M | 199M | 145M | 145M | 138M | 119M | 121M | 108M | 97.4M | 103M | 104M |
| Free Cash Flow | -376M | -208M | -124M | -96.8M | -52.2M | 185M | 54.9M | 51.6M | 475M | 725M | 665M |
| Ratios | |||||||||||
| ROE | -22.8% | -4.2% | -2.6% | -0.8% | 20.8% | -1.5% | 3.1% | 3.4% | 7.5% | 5.7% | 0.6% |
| ROA | -15.7% | -2.5% | -1.7% | -0.5% | 14.6% | -1.1% | 2.2% | 2.5% | 6.1% | 4.6% | 0.3% |
| Net Profit Margin | -56.4% | -8.9% | -5.2% | -1.4% | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% | 1.0% |
| Debt to Equity | 0.25x | 0.42x | 0.28x | 0.28x | 0.26x | 0.26x | 0.24x | 0.22x | 0.11x | 0.11x | 0.67x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biomarin Pharmaceutical Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 15.1M | 0.08 | 10.6% |
| 2021 | USD 3.39M | 0.02 | - |
| 2020 | USD 71.9M | 0.38 | 8.4% |
| 2019 | USD 11.1M | 0.06 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Biomarin Pharmaceutical Inc
- Insiders 0.34%
- Institutions 99.66%
- Public & others 0.00%
- Shares outstanding 194M
- Free float 193M
Top funds holding BMRN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Dodge & Cox Stock I | 9.77M | 5.04% | 0.00% | Sep 2026 |
| iShares Core S&P Mid-Cap ETF | 6.96M | 3.59% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 6.16M | 3.18% | +0.08% | Sep 2026 |
| Vanguard Capital Opportunity Inv | 5.32M | 2.75% | +3.02% | Sep 2026 |
| Vanguard PRIMECAP Inv | 5.21M | 2.69% | +4.82% | Sep 2026 |
| Vanguard Small Cap Index | 4.36M | 2.25% | -2.02% | Sep 2026 |
| Fidelity Contrafund | 3.15M | 1.63% | +11.00% | Sep 2026 |
| American Funds Cptl Wld Gr&Inc A | 2.58M | 1.33% | 0.00% | Sep 2026 |
| R-co Valor C EUR | 2.52M | 1.30% | -19.05% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.46M | 1.27% | +2.68% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 2.42M | 1.25% | -5.07% | Sep 2026 |
| First Trust NYSE Arca Biotech ETF | 1.79M | 0.92% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 1.49M | 0.77% | -0.32% | Oct 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 1.43M | 0.74% | +1.26% | Sep 2026 |
| PRIMECAP Odyssey Aggressive Growth | 1.43M | 0.74% | +0.56% | Sep 2026 |
| DFA U.S. Small Cap Value I | 1.37M | 0.71% | +68.66% | Sep 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 1.05M | 0.54% | +0.05% | Oct 2026 |
| DNB Global A | 1.00M | 0.52% | -4.43% | Sep 2026 |
| PRIMECAP Odyssey Growth | 981K | 0.51% | +0.21% | Sep 2026 |
| Dodge & Cox Balanced I | 955K | 0.49% | 0.00% | Sep 2026 |
Top institutions holding BMRN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 20.4M | 10.56% | +3.16% | Jun 2026 |
| Dodge & Cox | 14.8M | 7.66% | +1.94% | Jun 2026 |
| PRIMECAP Management Company | 14.2M | 7.33% | -0.03% | Jun 2026 |
| Vanguard Capital Management, LLC | 8.74M | 4.51% | +1.16% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 8.65M | 4.47% | +4.22% | Jun 2026 |
| NORGES BANK | 8.21M | 4.24% | +8.99% | Jun 2026 |
| State Street Corp | 7.80M | 4.03% | +6.93% | Jun 2026 |
| Viking Global Investors LP | 7.62M | 3.93% | +7.85% | Jun 2026 |
| Vestal Point Capital LP | 6.03M | 3.11% | +68.53% | Jun 2026 |
| AQR Capital Management LLC | 5.70M | 2.94% | -25.75% | Jun 2026 |
| FMR Inc | 4.82M | 2.49% | +35.21% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 4.40M | 2.27% | +7.93% | Sep 2026 |
| Geode Capital Management, LLC | 3.91M | 2.02% | +2.42% | Jun 2026 |
| Assenagon Asset Management SA | 3.52M | 1.82% | +83.49% | Jun 2026 |
| Capital Research Global Investors | 3.50M | 1.81% | +0.37% | Jun 2026 |
| Deep Track Capital, LP | 3.31M | 1.71% | +187.61% | Jun 2026 |
| Millennium Management LLC | 2.07M | 1.07% | -31.18% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.62M | 0.83% | +1.78% | Jun 2026 |
| First Trust Advisors L.P. | 1.61M | 0.83% | -3.96% | Jun 2026 |
| Northern Trust Corp | 1.56M | 0.80% | -1.78% | Jun 2026 |
Biomarin Pharmaceutical Inc company profile
- Company name
- Biomarin Pharmaceutical Inc
- Ticker
- BMRN.US
- Exchange
- USA Stocks
- Listed since
- Jul 23, 1999
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,221
- Fiscal year end
- December
- Address
- 770 Lindaro Street, San Rafael, CA, United States, 94901
- Phone
- 415 506 6700
- Website
- biomarin.com
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Biomarin Pharmaceutical Inc management
10- Mr. Alexander HardyPresident, CEO & Director · born 1969
- Mr. Brian R. Mueller CPACFO & Executive VP of Finance · born 1974
- Dr. C. Greg Guyer Ph.D.Executive VP & CTO · born 1962
- Ms. Cristin HubbardExecutive VP & Chief Commercial Officer
- Dr. Gregory Friberg M.D.Executive VP and Chief Research & Development Officer
- Ms. Rashmi Eshwar RamchandaniVP, Chief Accounting Officer & Principal Accounting Officer · born 1979
- Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early Development
- Mr. Arpit DaveExecutive Vice President, Chief Digital & Information Officer
- Mr. George Eric Davis J.D.Executive VP, Chief Legal Officer & Secretary · born 1971
- Ms. Cara Bauer Ph.D.Executive VP & Chief People Officer